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INCREASES in longevity of the general population world-wide are an unprecedented phenomenon with significant 
health and social impact. Although environmental factors 
have led to an increase in life span, there is ample evidence 
that genetic factors are involved in extreme longevity both 
in humans (1–7) and in other organisms (8). The protective 
genetic factors that lead to longevity are likely to involve 
fundamental processes of aging that may be different from 
those associated with early mortality or premature onset of 
age-related diseases in younger individuals. The mecha-
nisms of aging in humans are far from understood, but avail-
able evidence suggests that several pathways—inflammation, 
oxidative stress and stress responses, cellular senescence, 
DNA damage and repair, and the growth hormone or insulin-
like growth factor and insulin (GH, IGF, INS) axis—may 
play key roles (9–12). Model organisms suggest that inhibit-
ing the GH, IGF, or INS axis, which is involved in regulat-
ing cell proliferation, cell death, wound repair, and 
metabolism, may promote longevity by reducing oxidative 
stress and slowing the rate of cell replication and the accu-
mulation of somatic-cell DNA mutations (13). There is also 
evidence for other important pathways such as the heat-
shock proteins and heat-shock factors that are highly con-
served across species and play a role in prolongevity 
transcription pathways. Clinical and epidemiological inves-
tigations, including candidate gene studies, have suggested 
that inflammation pathways may affect life span and risk of 
age-related conditions such as cardiovascular disease (CVD) 
and its risk factors (14–19). A combination of multiple genetic 
variants may be required for an individual to achieve excep-
tional longevity, which may account in part for its rarity.
Two previous studies have used whole-genome screening 
to identify genetic variants associated with longevity 
(20,21). In a linkage analysis, the earliest report (20) identi-
fied a locus on chromosome 4 that has not been replicated. 
A recent report from the Framingham Heart Study (FHS) 
(22) identified modest associations between longevity (or 
age at death) and single-nucleotide polymorphisms (SNPs) 
in or near important candidate genes, including FOXO1A, 
GAPDH, KL, LEPR, PON1, PSEN1, SOD2, and WRN, but 
none of the associations achieved conventional levels of sta-
tistical significance; the sample size was modest, and the 
genotyping platform did not cover the genome well by cur-
rent standards. The advent of genome-wide association 
studies (GWAS) has successfully led to the discovery of 
novel genetic variants that have strong evidence for replica-
tion and that are outside of traditional candidate gene re-
gions for several common diseases (23–29). The detection 
of novel genetic variants associated with longevity holds the 
promise to provide important insights to biologic pathways 
in the aging process and thus the potential to develop inno-
vative strategies to promote a long and healthy life.
We conducted a meta-analysis of GWAS findings for lon-
gevity within an international consortium of four longitudi-
nal community-based cohort studies that followed adults 
over many years. Longevity was defined as survival to age 
90 years or older, and a comparison group was drawn from 
each cohort. Furthermore, we identified two independent 
cohorts of long-lived individuals, the Leiden Longevity 
Study cohort and the Danish 1905 cohort, to evaluate initial 
findings for the strongest allelic associations for longevity 
in a second discovery stage.
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Background. Genome-wide association studies (GWAS) may yield insights into longevity.
Methods. We performed a meta-analysis of GWAS in Caucasians from four prospective cohort studies: the Age, Gene/
Environment Susceptibility-Reykjavik Study, the Cardiovascular Health Study, the Framingham Heart Study, and the 
Rotterdam Study participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Con-
sortium. Longevity was defined as survival to age 90 years or older (n = 1,836); the comparison group comprised cohort 
members who died between the ages of 55 and 80 years (n = 1,955). In a second discovery stage, additional genotyping 
was conducted in the Leiden Longevity Study cohort and the Danish 1905 cohort.
Results. There were 273 single-nucleotide polymorphism (SNP) associations with p < .0001, but none reached the 
prespecified significance level of 5 × 10−8. Of the most significant SNPs, 24 were independent signals, and 16 of these 
SNPs were successfully genotyped in the second discovery stage, with one association for rs9664222, reaching 6.77 × 
10−7 for the combined meta-analysis of CHARGE and the stage 2 cohorts. The SNP lies in a region near MINPP1 (chro-
mosome 10), a well-conserved gene involved in regulation of cellular proliferation. The minor allele was associated with 
lower odds of survival past age 90 (odds ratio = 0.82). Associations of interest in a homologue of the longevity assurance 
gene (LASS3) and PAPPA2 were not strengthened in the second stage.
Conclusion. Survival studies of larger size or more extreme or specific phenotypes may support or refine these initial 
findings.
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Methods
Cohorts for Heart and Aging Research in Genomic 
Epidemiology Consortium
The Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium was convened to pro-
mote the discovery of new genomic loci involved in multiple 
complex traits in population-based follow-up studies using 
genome-wide association analysis (30). This meta-analysis 
used data from the CHARGE Consortium, which includes the 
Age, Gene/Environment Susceptibility-Reykjavik Study (AG-
ES-Reykjavik) (31), the Cardiovascular Health Study (CHS) 
(32), FHS (33–36), and the Rotterdam Study (RS) (37).
The AGES-Reykjavik was funded by the National Insti-
tute on Aging (NIA) and was designed to examine genetic 
susceptibility and environmental interactions as risk factors 
for disease and disability in old age. Detailed phenotyping 
of the cardiovascular, neurocognitive, musculoskeletal, and 
body composition and metabolism was conducted in 5,764 
men and women enrolled in 2002–2006 who were sampled 
from the 11,549 survivors of the AGES-Reykjavik of 30,000 
men and women sampled from the 1907–1935 birth cohort 
(31). The CHS is a National Heart Lung and Blood Institute 
(NHLBI) contract-funded cohort study designed to evaluate 
risk factors for coronary heart disease (CHD) and stroke in 
older adults (32). Participants (n = 5,201) were recruited 
in 1989–1990, with an additional 687 minorities recruited 
in 1992–1993. The FHS is an NHLBI contract-funded co-
hort study initiated in 1948 to study determinants of CVD 
and other major illnesses. The original cohort comprised 
5,209 men and women aged 28–62 years at enrollment who 
have undergone routine biennial examinations (33,34). In 
1971, 5,124 offspring of the original cohort participants and 
offspring spouses, aged 5–70 years, were enrolled into the 
Framingham Offspring Study. Offspring participants have 
been examined approximately every 4–8 years (35,36). In 
the 1990s, DNA was obtained for genetic studies from sur-
viving original cohort and offspring participants. The RS 
was planned and designed in the early 1990s as a longitudi-
nal study investigating the incidence and progression of dis-
eases in the elderly participants. From 1991 to 1995, all 
inhabitants of Ommoord, a district of Rotterdam in the 
Netherlands, who were aged 55 years or older, were invited 
to participate in this study (38). Of 10,275 eligible individu-
als, 7,983 agreed to participate (78%). The participants in 
the CHARGE studies are Caucasian by self-report. In each 
CHARGE study, population structure was assessed using 
principal components analysis, and outliers were removed. 
Any remaining within-study structure was adjusted for us-
ing appropriate methods (39). The details of each participat-
ing cohort study’s genotyping platform, imputation 
algorithm, and quality control procedures used by each 
study are summarized in Supplementary Table 1. Each study 
was approved by the respective Institutional Review Board, 
and all participants provided consent.
Longevity and Comparison Group Definitions
In the present study, achievement of longevity was de-
fined as reaching age 90 years or older, regardless of whether 
the participants were still living or had since died. Geno-
typed participants from these studies who died between the 
ages of 55 and 80 years were used as the comparison group. 
The comparison group was limited to deceased participants 
to ensure that no one in the comparison group could subse-
quently achieve longevity. The minimum age at death was 
set to match the minimum age at enrollment in the RS to 
promote age comparability of the comparison group across 
the four cohorts. The maximal age at death in the compari-
son group was set arbitrarily at age 80 years to include the 
majority of deaths, to maximize the overlap between birth 
cohorts, and to exclude those persons who survived far be-
yond average life expectancy for their respective birth co-
hort, that is persons who nearly reached longevity. Because 
of the timing of recruitment, DNA collection, and death, 
there was only partial overlap of the birth cohorts included 
in the comparison groups and the group of persons achiev-
ing longevity. Only Caucasian participants were included. 
Across the four studies, there were 1,836 persons who 
achieved longevity (144 from AGES-Reykjavik, 557 from 
CHS, 362 from FHS, and 773 from the RS), and the com-
parison group had 1,955 participants (122, 544, 355, and 
934 participants from the AGES-Reykjavik, CHS, FHS, and 
RS, respectively). To facilitate comparison of results across 
studies, we imputed to 2.5 million SNPs using the HapMap 
Centre d’Etude du Polymorphisme Humain European 
Ancestry–genotyped samples as a reference. The effective 
sample size for all but one of the top SNPs was more than 
80% of the full sample size of 3,791, indicating that the 
SNPs that were not directly genotyped were imputed well in 
most studies.
Second Discovery Stage Genotyping
Among the top 24 independent regions with the strongest 
associations for longevity in the four-study meta-analysis 
(p < 10−4), we selected the 22 SNPs that had been tested in all 
four CHARGE cohorts in two additional Caucasian cohorts: 
the Leiden Longevity Study cohort and the Danish 1905 
cohort. We excluded the two SNPs that could not be geno-
typed or imputed in all four CHARGE cohorts. Of the 22 
SNPs selected for genotyping, 2 could not be genotyped 
and 4 did not pass quality control procedures; thus, 16 SNPs 
were analyzed in the second stage.
In the “Leiden Longevity Study” (7,40), a total of 950 
long-lived proband siblings (mean age 94 years, range 89–
104 years), 1,750 offspring (mean age 61 years, range 39–
81 years), and 758 partners of offspring (mean age 60 years, 
range 36–79 years) were included. The additional genotyp-
ing of selected SNPs was undertaken in all 950 long-lived 
probands, and these were compared with the 744 partners of 
their offspring and an additional 680 blood bank donors 
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(60% men, mean age 31 years, range 18–40 years). All 
long-lived individuals and the comparison groups were 
from the Leiden area in the Netherlands and of European 
ancestry.
Participants in the “Danish 1905 Cohort Survey” are from 
the Danish 1905 birth cohort ascertained in 1998 when they 
were aged 92–93 years (41). Of the 3,600 participants alive 
from that cohort, 2,262 participants enrolled in the study. 
Participants underwent a home-based interview on health 
and lifestyle parameters, physical and cognitive tests, and 
collection of biologic material. The current genetic study 
comprises a total of 1,644 participants from this survey, 
mean age 93 years (range 92–93 years), 28% men. A com-
parison group included 2,007 Caucasians who were twins 
(one twin per pair) collected from all over Denmark, with a 
mean age of 57 years (range 46–68 years), 45% men.
Second Discovery Stage Genotyping Methods
Genotyping of the selected SNPs was performed using 
an iPLEX genotyping assay developed for use with the 
MassARRAY platform (Sequenom, Inc., San Diego, CA) 
(42). The iPLEX genotyping assay is based on mass spec-
trometry and enables genotyping of 25–36 custom SNPs on 
a sample in a single reaction. For the purposes of quality 
control, the system first automatically calls the genotypes 
and then generates cluster plots for all SNPs that are in-
spected individually by experienced technicians who check 
whether the plots show clear separation of the genotype 
clusters. There were two SNPs that did not pass quality con-
trol and two SNPs where no heterozygotes could not be de-
tected; thus, lack of Hardy–Weinberg equilibrium was the 
quality control. Negative controls were included in the 
genotyping procedure (8 per 384-well plate), and impor-
tantly, 4% of samples were genotyped twice to confirm re-
producibility (reproducibility was ≥99.7%).
Statistical Analysis
Using logistic regression, each imputed and observed 
HapMap SNP was tested for association with the longevity 
outcome using an additive genetic model adjusting for sex. 
The mean dosage of one of the alleles (a value between 0 
and 2) was the predictor for imputed SNPs. The CHS addi-
tionally adjusted for field study site in the regression model, 
and the FHS used generalized estimating equations to ac-
count for familial correlations. We used the ratio of observed 
to expected variance in the imputed SNP genotype counts 
as a quality control metric for imputed SNPs (43). This ra-
tio, multiplied by the sample size, is an estimate of the ef-
fective sample size. In the imputation software MaCH, this 
ratio is called r2 as it is an estimate of the allelic correlation 
between the imputed genotypes and the true genotypes for 
the SNP. A total of 2,287,520 SNPs that had average minor 
allele frequency greater than 0.01 and were genotyped or 
imputed in all studies with variance ratio greater than 0.1 
were meta-analyzed. The study-specific inflation factors 
(lGC) were computed using the set of chi-square statistics 
used for the meta-analysis for each study. The inflation fac-
tor is computed as the median of all chi-square statistics 
divided by the expected median of the statistics (approxi-
mately 0.456) for a chi-square distribution with 1 df. We 
calculated a meta-analysis odds ratio (OR) for each SNP 
using a fixed-effects model that combined logistic regres-
sion parameters and standard errors across the studies using 
inverse variance weights. The meta-analysis OR represents 
the increase in log-odds of surviving to age 90 years or older 
versus dying between ages 55 and 80 years for each addi-
tional copy of the minor allele of the SNP. SNP associations 
were considered to be significant on a genome-wide level at 
p < 5 × 10−8. The 16 SNPs in the second discovery phase 
effort were analyzed in the two study samples using an ad-
ditive model. The results were added to the previous meta-
analysis using a fixed-effects model as described earlier. 
Finally, using the top 24 results, we conducted a pathway 
analysis with the Database for Annotation, Visualization 
and Integrated Discovery (http://david.abcc.ncifcrf.gov/).
Results
Table 1 provides the characteristics of the persons achiev-
ing longevity and the comparison group in each of the four 
CHARGE discovery cohorts at the time of DNA collection. 
In line with the design of the study, persons achieving lon-
gevity were 10–20 years older than participants in the com-
parison group at baseline and were more likely to be women. 
Between 45% and 83% of those achieving longevity were 
still alive at the time that longevity status was ascertained. 
Among those who had died, the distributions of causes of 
death differed between those achieving longevity and the 
comparison group. Whereas 6%–12% of those achieving 
longevity died of cancer, more than 30% of the comparison 
group had death attributed to cancer. The prevalence of dia-
betes and a history of ever smoking were higher in the com-
parison group than in persons achieving longevity. The 
baseline prevalence of other cardiovascular risk factor lev-
els showed substantial overlap between the two groups.
The genomic control inflation factor lambda (lGC) for 
each cohort was less than 1.05 (45). After meta-analysis, 
overall inflation of the meta-analysis p values was minor 
(lGC = 1.034; Figure 1). None of the SNP–longevity asso-
ciations achieved the prespecified level of genome-wide 
significance of p < 5 × 10−8 (Figures 1 and 2). There were 
273 SNP associations with meta-analysis p < 10−4, and of 
these, 7 SNP associations had p < 10−5 (Supplementary 
Table 2). Under the null hypothesis that there are no asso-
ciations in the genome, we would expect 0.0001 × ~2.3 mil-
lion = ~230 hits. Table 2 shows the top 24 independent 
SNPs associated with longevity along with the number of 
supporting SNPs (additional SNPs with linkage disequilib-
rium r2 > .80 and p < 10−4). Thus, for example, there were 
NEWMAN ET AL.482
Table 1. Characteristics of Longevity Cases and Comparison Group at DNA Collection
Characteristic, M (SD) or %
CHS Framingham Heart Study Rotterdam Study AGES-Reykjavik
Survival Age to  
>90 y, n = 557
Comparison  
Group, n = 544
Survival Age to  
>90 y, n = 362
Comparison  
Group, n = 355
Survival Age to  
>90 y, n = 773
Comparison  
Group, n = 934
Survival Age to  
>90 y, n = 144
Comparison  
Group, n = 122
Age at DNA draw, y 79.6 (4.5) 69.5 (3.0) 87.3 (3.8) 66.5 (6.9) 83.7 (5.53) 66.5 (5.37) 88.0 (2.4) 73.8 (3.2)
Women, % 61 54 70 34 79 41 56 43
Alive, % 45 0 36 0 33 0 83 0
Cause of death*
 CVD, % 39 33 22 23 34 32 48 39
 Cancer, % 10 40 9 45 6 39 12 38
 Other, % 50 27 57 25 52 27 40 23
 Unknown, % 0.3 0.2 12 6 7 2 0 0
Body mass index, kg/m2 25.5 (3.9) 26.6 (5.2) 26.0 (4.1) 28.0 (5.5) 26.8 (3.81) 26.3 (3.75) 25.9 (4.0) 27.4 (4.7)
Ever smoker, % 40 70 54 81.0 29 43 49.3 80
Hypertension, % 57 53 68 75 40 40 83 80
Diabetes, % 8 20 8 22 6 8 8 11
Total cholesterol, mg/dL 210.5 (40.2) 212.2 (38.7) 198.8 (38.1) (204.7 (47.1) 248 (49.4) 254 (46.8) 207.6 (44.3) 224.44 (42.7)
Notes: In the CHS, ever smoking was defined as having smoked more than 100 cigarettes or five packs during the participant’s lifetime; hypertension was defined 
as a systolic blood pressure 140 mmHg or more or a diastolic blood pressure 90 mmHg or more or a history of hypertension and taking antihypertensive medication; 
diabetes was defined as fasting glucose more than 125 mg/dL or use of insulin or oral hypoglycemic medications. In Framingham Heart Study, ever smoking was 
defined as self-reported cigarette smoking of at least 1 cigarette/d for a year at any attended examination; total serum cholesterol was measured using an automated 
enzymatic procedure (44); hypertension was defined as blood pressure 140/90 mmHg or more or on antihypertensive medication; diabetes was defined as fasting 
blood glucose more than 125 mg/dL, a random blood glucose of more than 200 mg/dL, or use of insulin or oral hypoglycemic agents. In the Rotterdam Study, ever 
smoking was defined as self-reported ever smoking (cigarette, cigar, or pipe); hypertension was defined as systolic blood pressure 160 mmHg or more and/or diastolic 
blood pressure 100 mmHg or more and/or blood pressure–lowering medication with an indication for hypertension; total serum cholesterol was measured using an 
automated enzymatic procedure (40); diabetes was defined as self-reported diabetes at baseline. In the AGES-Reykjavik, ever smoking was defined as having smoked 
more than 100 cigarettes in one’s lifetime; total serum cholesterol was measured using an automated enzymatic procedure (40); hypertension was defined as systolic 
blood pressure 140 mmHg or more, diastolic blood pressure 90 mmHg or more, use of antihypertensive medications, or self-report; diabetes was defined as fasting 
glucose more than 125 mg/dL, use of insulin or oral hypoglycemic medications, or self-report. AGES-Reykjavik = Age, Gene/Environment Susceptibility-Reykjavik 
Study; CHS = Cardiovascular Health Study; CVD = cardiovascular disease.
* As a proportion of all deaths for those in the survival to age 90 years or older group.
19 supporting SNPs on chromosome 15 in or near the lon-
gevity assurance homologue 3 (LASS3) gene, with the 
strongest association (OR = 0.79, p = 1.2 × 10−5) noted for 
rs8029244. The study-specific ORs for the 24 SNP associa-
tions shown in Table 2 were in the same direction and were 
of similar magnitude across the four cohorts (Figure 3; 
Supplementary Table 3).
Of the 24 strongest independent regions shown in Table 2, 
the 22 SNPs tested in all four CHARGE cohorts were 
selected for further evaluation, and 16 were successfully 
genotyped in the second stage cohorts. Only 1 of the 16 
SNPs had a smaller p value after including the replication 
Figure 1. Quantile–quantile plot for the 2,287,520 single-nucleotide poly-
morphisms in the meta-analysis of survival to age 90 years or older.
Figure 2. Plot of genome-wide association study for longevity meta-analysis 
(persons surviving to age ≥90 years, n = 1,836, and comparison group, n = 1,955) 
showing the −log10 (p values) based on the fixed-effects meta-analysis by chro-
mosome. Line indicates threshold for genome-wide significance of 5 × 10−8.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































studies in a joint meta-analysis, with the p value decreasing 
about 10-fold, from 1.61 × 10−5 to 6.77 × 10−7 and corre-
sponding OR of 0.82. This SNP, rs9664222, is ~25 kb from 
the MINPP1 gene (Figure 4). In the CHARGE analysis, the 
minor allele was associated with a lower odds of survival 
past age 90 (OR = 0.77). The Leiden study yielded a similar 
effect estimate (OR = 0.76, p = .0014), whereas the Danish 
study showed a nonsignificant trend in the same direction 
(OR = 0.92, p = .19). Findings for the other SNPs were in-
consistent in direction of association such that the meta-
analysis p values increased with inclusion of the second 
stage cohorts (Supplementary Table 3). Pathway analysis 
did not reveal significant findings in the top associations, 
though some groupings were biologically plausible.
Discussion
The CHARGE Consortium collaboration allowed us to 
conduct a meta-analysis of GWAS for longevity in a sample 
of long-lived individuals and a corresponding comparison 
group derived from the same longitudinal community-based 
cohort studies. Although none of the SNP associations for 
longevity in the first discovery phase achieved prespecified 
level of genome-wide significance, a polymorphism associ-
ated with the MINPP1 genes was among the strongest as-
sociations observed in our sample, with effect sizes that 
were similar within the four cohorts. The finding related to 
the MINPP1 gene was strengthened after including two ad-
ditional cohorts in a second discovery phase but did not 
reach genome-wide significance. Among the top 10 associa-
tions in the initial meta-analysis, additional SNP associa-
tions of potential interest in longevity include SNPs in or 
near LASS3, ACCN1, IL20RB, and PAPPA2. These SNPs 
Figure 3. Study-specific odds ratios (ORs) and 95% confidence intervals for 
MINPP1 (rs9664222) longevity association.
Note: AGES-Reykjavik = Age, Gene/Environment Susceptibility-Reykjavik 
Study; CHS = Cardiovascular Health Study; FHS = Framingham Heart Study.
Figure 4. Regional plot for rs9664222 near MINPP1.
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are near genes that have not previously been reported to be 
associated with longevity in human populations but are in-
teresting because these genes are conserved in basic bio-
logic pathways.
The MINPP1 gene codes multiple inositol polyphosphate 
phosphatases, which are compartmentalized to the endo-
plasmic reticulum lumen. MINPP1-deficient mice have no 
obvious defects, though targeted deletion in vitro is associ-
ated with slowed cellular proliferation (46). There is no evi-
dence that this SNP is functional; furthermore, its distance 
from the gene shows that it is not in strong linkage disequi-
librium with SNPs in MINPP1 (47). However, it is well 
known that important regulatory elements are found outside 
of genes. This SNP is within 50 kb of two copy number 
variants. The finding of an SNP near a gene regulating pro-
liferation is intriguing because of the higher rate of cancer 
death in the comparison group.
The initial finding in the LASS3 gene region was of inter-
est because of the historical association of its homologue 
with longevity in yeast (46). The LASS gene family contains 
a group of highly conserved genes that are found in all eu-
karyotic species. LASS isoforms are mammalian homo-
logues of the yeast longevity assurance gene 1, which 
encodes a protein that regulates life span (48). The strongest 
association was noted for rs8029244; this SNP is in the in-
tronic enhancer region of the LASS3 gene. LASS3 is a mem-
ber of the ceramide synthase family, which is important in 
sphingolipid metabolism, cell differentiation, cell cycling, 
and apoptosis (46). LASS3 may be involved in sphingolipid 
synthesis or its regulation (49).
IL20RB, interleukin 20 receptor beta IL-20, plays a role 
in skin inflammation and the development of hematopoi-
etic cells (50) and is of interest because of the strong asso-
ciations of inflammation with the aging process (51). IL-20 
is a pleiotropic cytokine with potent inflammatory, angio-
genic, and chemoattractive characteristics and is involved 
in inflammatory diseases, such as psoriasis, atherosclero-
sis, and rheumatoid arthritis (50). The ACCN1 gene en-
codes amiloride-sensitive sodium channels with two 
hydrophobic transmembrane regions and a large extracel-
lular loop, which has many cysteine residues with con-
served spacing (52,53). The member encoded by this gene 
may play a role in neurotransmission. ACCN1 was found to 
be associated with multiple sclerosis (54). Pregnancy-asso-
ciated plasma protein A2 (PAPPA2) is a metalloproteinase 
regulating local insulin-like growth factor pathway action 
(55). Genetic deletion extends life span in the mouse by 
30%–40% (56) and is characterized by delay in thymic in-
volution (57) and low rates of tumor incidence (56). Al-
though the associations reported here did not reach the a 
priori specified level of significance, the findings are im-
portant to report so that they can be replicated in studies 
without whole-genome genotyping and compared with fu-
ture studies, such as in centenarian studies and family stud-
ies of longevity. Effect size estimates noted here support 
the likelihood that longevity is a complex process, in that 
there were no variants with large effects, supporting the 
hypothesis that there may be many genes with small effects 
that contribute to longevity.
The strengths of this study include the community-based 
prospective design and the long-term follow-up of these co-
horts. In all cases, vital status was confirmed using death 
certificates and hospital records. Another strength was our 
ability to use controls that were equally well characterized 
and were drawn from within the same cohorts. The number 
of long-lived individuals reported here is very large relative 
to other studies in the literature, allowing greater ability to 
identify SNPs with small effects. The cohorts were rela-
tively homogeneous with respect to ancestry, limited to 
Caucasians of European decent. Our top associations were 
homogeneous across cohorts. Screening for latent popula-
tion substructure also supported ethnic homogeneity. Thus, 
the findings reported are less likely to be due to population 
stratification.
There are important aspects of the study that need to be 
kept in mind when interpreting the results. The differences 
in causes of death in the longevous individuals versus the 
comparison groups are expected as death from cancer tends 
to occur earlier in life than death from heart disease or de-
mentia. Many of the long-lived people are still alive and we 
do not yet know what their ultimate cause of death will be, 
but it is likely that cancer will be underrepresented among 
persons achieving longevity. Power remains a limitation. 
Thus, future GWAS aiming to identify variants for this phe-
notype will have to consider small effect sizes and target a 
sample size larger than our nearly 2,000 long-lived persons. 
DNA collection in cohort studies is a recent enough phe-
nomenon that relatively few cohort members who had DNA 
collected have had the opportunity to survive to age 90 
years. Continuous study of these and other similarly 
designed cohorts will allow us to extend this study to larger 
numbers and to older ages.
In our case comparison analysis, we attempted to account 
for birth cohort, but the overlap between birth year of the 
comparison group and of the long-lived participants was 
limited. Further follow-up of these cohorts is needed to in-
crease our ability to examine potential birth cohort effects. 
The study design of the cohorts examined in the second 
stage was different from the initial four-study CHARGE 
meta-analysis in that the comparison groups were derived 
from younger participants, living and deceased, who were 
not from the same cohort as the individuals achieving lon-
gevity. Certainly, there are important environmental factors 
that would be necessary for the fulfillment of the genetic 
potential for longevity. Heterogeneity in environmental ex-
posures and gene–environment interactions require further 
study. Finally, these results cannot be extended to popula-
tions of other ancestry.
In conclusion, this meta-analysis of GWAS data for 
longevity from four large cohorts and two additional 
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cohorts has implicated several genes involved in conserved 
basic mechanisms of cellular function. Analysis of more 
extreme survival phenotypes such as centenarians, addi-
tional follow-up to increase sample size in these cohorts for 
this phenotype, or evaluation of more specific phenotypes 
such as disease-free survival may support and refine these 
initial findings.
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